Moderna Inc. (NASDAQ: MRNA) announced that its phase 3 trial of mRNA-1647, an investigational cytomegalovirus vaccine, did not meet its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE